IDEXX upgraded to Buy from Hold at Canaccord As previously reported Canaccord upgraded IDEXX to Buy from Hold. The firm expects the Q4 launch of Catalyst One to drive share gain in the lower-volume vet market and drive IDEXX's revenue growth in 2015. Price target raised to $146 from $116.
News For IDXX From The Last 14 Days
Check below for free stories on IDXX the last two weeks.